Form 4: Immunocore R&D Head Sells Shares After Option Exercise

Immunocore's Head of R&D, David M. Berman, executed a pre-planned sale of company shares following the exercise of employee stock options.

Summary

• David M. Berman, Head of R&D at Immunocore Holdings plc, reported transactions involving the company's ordinary shares.
• On September 10, 2025, Berman exercised employee share options to acquire 31,338 ordinary shares at an exercise price of $17.46 per share.
• Immediately following the exercise on September 10, 2025, Berman sold 30,138 ordinary shares at a weighted average price of $36.12, with prices ranging from $35.66 to $36.65.
• An additional 1,200 ordinary shares were sold on September 10, 2025, at a weighted average price of $36.77, with prices ranging from $36.66 to $36.90.
• On September 11, 2025, Berman exercised more employee share options to acquire 19,081 ordinary shares at an exercise price of $17.46 per share.
• Following this second exercise on September 11, 2025, Berman sold all 19,081 acquired ordinary shares at a weighted average price of $36.28, with prices ranging from $35.91 to $36.63.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Berman on May 9, 2025.
• After these transactions, Berman's direct beneficial ownership of ordinary shares from these specific exercises is 0, but he retains 221,371 employee share options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive to neutral. While an insider selling shares can sometimes be viewed negatively, these transactions were pre-planned under a Rule 10b5-1 plan, indicating a routine monetization of vested equity compensation rather than a reaction to new company-specific news. The executive realized a significant profit, which is a positive outcome for the individual and reflects well on the company's stock performance.

Positives

• The Head of R&D is realizing value from his compensation package by exercising options at a significant profit, indicating the company's stock performance has been favorable.
• Transactions were conducted under a pre-established Rule 10b5-1 trading plan, which suggests a disciplined approach to managing personal holdings and reduces concerns about opportunistic insider selling.

Negatives

• The Head of R&D has reduced his direct ownership of ordinary shares by selling all shares acquired through option exercises on these dates, which could be perceived as a reduction in direct alignment with shareholder interests, although common for executive compensation.

Risks

• Potential for negative market perception if investors misinterpret the routine nature of insider sales, especially when executives reduce their direct shareholdings.

Future Outlook

The transactions reflect a pre-planned monetization of vested equity compensation by a key executive, as outlined in a Rule 10b5-1 trading plan. This does not provide new forward-looking guidance on the company's operational or financial performance.

Management Comments

• The reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

Industry Context

This filing represents a routine insider transaction common in the biotechnology and pharmaceutical sectors, where executives often receive a significant portion of their compensation in the form of equity, including stock options. The exercise and sale of options under a pre-arranged 10b5-1 plan is a standard practice for executives to manage their personal finances and diversify their holdings, while adhering to insider trading regulations.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance, providing an affirmative defense against insider trading allegations by pre-scheduling transactions.
• The monetization of vested stock options is a common component of executive compensation across the life sciences industry, similar to practices observed at companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals, where executives periodically exercise and sell shares to realize value from their equity awards.
• The profit realized from the option exercises (selling at approximately $36 per share after exercising at $17.46) indicates a healthy appreciation in Immunocore's stock price since the options were granted, which is a positive sign for long-term shareholders, comparable to successful drug development companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider transaction. It does not signal a change in company fundamentals.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The reporting person continues to hold 221,371 employee share options, which may be exercised in the future prior to their expiration date of September 12, 2028.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions executed under a pre-established Rule 10b5-1 trading plan. Such transactions, while involving a significant executive, typically do not provide new fundamental information about the company's operational performance or future outlook. Therefore, it does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate for investors awaiting more substantive company updates.

Keywords

Immunocore, IMCR, Form 4, Insider Trading, Stock Options, Share Sale, David M. Berman, R&D, Beneficial Ownership, Rule 10b5-1